Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milatuzumab in Chronic Lymphocytic Leukemia
NCT00603668Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2008
- Primary completion
- Jan 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of milatuzumab in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), sponsored by Gilead Sciences. Primary endpoint: Safety of the anti-CD74 antibody at 12 weeks. Started Aug 2008; status: completed.
02
Drugs
milatuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00603668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00603668.